The Beta-Blocker Her Own Chart Almost Called For
Her blood pressure chart looks like ordinary resistant hypertension, the kind that usually earns a beta-blocker without much debate. The diagnosis underneath it makes that same reflexive choice dangerous.
S.K., a 45-year-old woman, has taught yoga for almost fifteen years and describes herself, only half joking, as someone who thought her blood pressure problem was ironic given how much of her life is built around teaching people to relax. She has had episodic, severe hypertension for the past eight months — sudden spikes to systolic pressures over 200, accompanied by pounding headaches, palpitations, and drenching sweats that resolve over twenty to thirty minutes — initially treated by an urgent care clinic as isolated hypertensive episodes with as-needed medication, without a clear diagnosis attached. Between episodes her blood pressure runs entirely normal, which is part of why the pattern took months to be recognized as something other than ordinary stress-related spikes.
A more complete workup, prompted by the episodic pattern rather than a sustained one, found markedly elevated plasma metanephrines and a 3.2-centimeter adrenal mass on imaging, consistent with pheochromocytoma. Her case arrives at cardiology with a standing as-needed metoprolol order already in her chart from the urgent care visits, written before the diagnosis was known — and starting a beta-blocker in an undiagnosed or newly diagnosed pheochromocytoma patient before establishing alpha-blockade is a recognized, dangerous sequencing error. Catecholamine excess in pheochromocytoma stimulates both alpha-mediated vasoconstriction and beta-2-mediated vasodilation simultaneously; beta-blockade removes the vasodilating counterbalance while leaving unopposed alpha-mediated vasoconstriction unchecked, which can precipitate a hypertensive crisis rather than control one. Beta-1 selectivity does not exempt an agent from this: metoprolol's selectivity is relative and falls away as the dose rises, and crises have been described with selective agents. The correct sequence, well established in endocrine and surgical literature, is alpha-blockade first, typically achieved over one to two weeks before any beta-blocker is considered, and only if reflex tachycardia from the alpha-blockade itself then requires it.
At the endocrine/cardiology co-management consultation
The standing metoprolol order needs to come off her chart before anyone reflexively uses it during her next episode. Beta-blockade before alpha-blockade in pheochromocytoma is a recognized, dangerous sequencing error — it removes the beta-2-mediated vasodilation that's partially offsetting her alpha-driven vasoconstriction, and metoprolol being beta-1-selective doesn't protect her, since that selectivity is only relative, and can precipitate a hypertensive crisis rather than treat one.
Fully agreed, and I want to make sure the sequencing gets communicated clearly to anyone else who might see her acutely, not just documented in a note. Alpha-blockade first, typically over one to two weeks to establish adequate blockade before any beta-blocker is even considered.
Starting doxazosin, titrating over the next one to two weeks with a target of mild orthostatic hypotension as the clinical endpoint indicating adequate alpha-blockade. She also needs deliberate volume repletion alongside it — a high-sodium diet and generous fluids once blockade begins — because chronic catecholamine excess leaves her intravascularly contracted, and unblocking that vasoconstriction without refilling the tank is what produces the profound hypotension people run into at induction. Metoprolol only added afterward, and only if she develops reflex tachycardia from the alpha-blockade itself — not before, and not for her hypertension directly.
Doxazosin started and titrated over the following two weeks, targeting mild orthostatic hypotension as the endpoint for adequate alpha-blockade, with high-sodium intake and liberal fluids started alongside it for volume repletion. Standing PRN metoprolol order removed from her chart. Surgical planning for adrenalectomy proceeding once alpha-blockade is established.
Agreed without disagreement on the sequencing itself; the operational lesson flagged for the practice, not just her chart:
The standing metoprolol order had been written by a clinician who saw only her hypertension pattern, not the eventual diagnosis — a reminder that any patient with truly episodic, severe hypertensive spikes deserves consideration of a catecholamine-excess workup before a reflexive beta-blocker order gets left in place.